Repare Therapeutics Inc.

NasdaqGS:RPTX Voorraadrapport

Marktkapitalisatie: US$119.5m

Repare Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Repare Therapeutics is Lloyd Segal, benoemd in Sep2016, heeft een ambtstermijn van 8.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 4.99M, bestaande uit 12.3% salaris en 87.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.28% van de aandelen van het bedrijf, ter waarde $ 331.21K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.5 jaar en 4.7 jaar.

Belangrijke informatie

Lloyd Segal

Algemeen directeur

US$5.0m

Totale compensatie

Percentage CEO-salaris12.3%
Dienstverband CEO8.2yrs
Eigendom CEO0.3%
Management gemiddelde ambtstermijn5.5yrs
Gemiddelde ambtstermijn bestuur4.7yrs

Recente managementupdates

Recent updates

Analysts' Revenue Estimates For Repare Therapeutics Inc. (NASDAQ:RPTX) Are Surging Higher

Nov 13
Analysts' Revenue Estimates For Repare Therapeutics Inc. (NASDAQ:RPTX) Are Surging Higher

There's No Escaping Repare Therapeutics Inc.'s (NASDAQ:RPTX) Muted Revenues Despite A 35% Share Price Rise

Oct 05
There's No Escaping Repare Therapeutics Inc.'s (NASDAQ:RPTX) Muted Revenues Despite A 35% Share Price Rise

Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data

Aug 30

Will Repare Therapeutics (NASDAQ:RPTX) Spend Its Cash Wisely?

Jul 12
Will Repare Therapeutics (NASDAQ:RPTX) Spend Its Cash Wisely?

Repare Therapeutics Inc.'s (NASDAQ:RPTX) 34% Dip In Price Shows Sentiment Is Matching Revenues

May 01
Repare Therapeutics Inc.'s (NASDAQ:RPTX) 34% Dip In Price Shows Sentiment Is Matching Revenues

Benign Growth For Repare Therapeutics Inc. (NASDAQ:RPTX) Underpins Stock's 30% Plummet

Mar 12
Benign Growth For Repare Therapeutics Inc. (NASDAQ:RPTX) Underpins Stock's 30% Plummet

We Think Repare Therapeutics (NASDAQ:RPTX) Needs To Drive Business Growth Carefully

Feb 15
We Think Repare Therapeutics (NASDAQ:RPTX) Needs To Drive Business Growth Carefully

Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Fly 30% But Investors Aren't Buying For Growth

Dec 20
Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Fly 30% But Investors Aren't Buying For Growth

Here's Why We're Not At All Concerned With Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation

Oct 24
Here's Why We're Not At All Concerned With Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation

New Forecasts: Here's What Analysts Think The Future Holds For Repare Therapeutics Inc. (NASDAQ:RPTX)

Aug 14
New Forecasts: Here's What Analysts Think The Future Holds For Repare Therapeutics Inc. (NASDAQ:RPTX)

Analysts Are Betting On Repare Therapeutics Inc. (NASDAQ:RPTX) With A Big Upgrade This Week

May 14
Analysts Are Betting On Repare Therapeutics Inc. (NASDAQ:RPTX) With A Big Upgrade This Week

Analysts Are Upgrading Repare Therapeutics Inc. (NASDAQ:RPTX) After Its Latest Results

May 12
Analysts Are Upgrading Repare Therapeutics Inc. (NASDAQ:RPTX) After Its Latest Results

Repare Therapeutics Inc. (NASDAQ:RPTX) Looks Inexpensive But Perhaps Not Attractive Enough

May 08
Repare Therapeutics Inc. (NASDAQ:RPTX) Looks Inexpensive But Perhaps Not Attractive Enough

Growth Investors: Industry Analysts Just Upgraded Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts By 31%

Mar 03
Growth Investors: Industry Analysts Just Upgraded Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts By 31%

Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth

Oct 27
Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth

Repare Therapeutics: Budding Synthetic Lethality Player With 3 Big Pharma Partners

Sep 07

Repare Therapeutics GAAP EPS of -$0.91 misses by $0.06, revenue of $0.67M

Aug 04

Repare Therapeutics: Interesting Gene Editing Company, But Miles To Go

Jun 27

Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth

Jun 24
Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth

Repare Therapeutics (NASDAQ:RPTX) Is In A Good Position To Deliver On Growth Plans

Mar 02
Repare Therapeutics (NASDAQ:RPTX) Is In A Good Position To Deliver On Growth Plans

We're Not Worried About Repare Therapeutics' (NASDAQ:RPTX) Cash Burn

Oct 14
We're Not Worried About Repare Therapeutics' (NASDAQ:RPTX) Cash Burn

We Think Repare Therapeutics (NASDAQ:RPTX) Can Easily Afford To Drive Business Growth

Apr 16
We Think Repare Therapeutics (NASDAQ:RPTX) Can Easily Afford To Drive Business Growth

Have Repare Therapeutics Inc. (NASDAQ:RPTX) Insiders Been Selling Their Stock?

Mar 12
Have Repare Therapeutics Inc. (NASDAQ:RPTX) Insiders Been Selling Their Stock?

Analyse CEO-vergoeding

Hoe is Lloyd Segal's beloning veranderd ten opzichte van Repare Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$84m

Jun 30 2024n/an/a

-US$69m

Mar 31 2024n/an/a

-US$46m

Dec 31 2023US$5mUS$615k

-US$94m

Sep 30 2023n/an/a

-US$97m

Jun 30 2023n/an/a

-US$3m

Mar 31 2023n/an/a

-US$29m

Dec 31 2022US$4mUS$592k

-US$29m

Sep 30 2022n/an/a

-US$26m

Jun 30 2022n/an/a

-US$132m

Mar 31 2022n/an/a

-US$120m

Dec 31 2021US$4mUS$572k

-US$107m

Sep 30 2021n/an/a

-US$94m

Jun 30 2021n/an/a

-US$77m

Mar 31 2021n/an/a

-US$62m

Dec 31 2020US$5mUS$505k

-US$53m

Sep 30 2020n/an/a

-US$46m

Jun 30 2020n/an/a

-US$40m

Mar 31 2020n/an/a

-US$35m

Dec 31 2019US$2mUS$430k

-US$27m

Compensatie versus markt: De totale vergoeding ($USD 4.99M ) Lloyd } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 647.72K ).

Compensatie versus inkomsten: De vergoeding van Lloyd is gestegen terwijl het bedrijf verliesgevend is.


CEO

Lloyd Segal (60 yo)

8.2yrs

Tenure

US$4,991,804

Compensatie

Mr. Lloyd Mitchell Segal serves as Director at HotKnot Therapeutics, Inc. Mr. Segal has been the Chief Executive Officer, President and Director of Repare Therapeutics Inc. since September 2016. Mr. Segal...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Lloyd Segal
President8.2yrsUS$4.99m0.28%
$ 331.2k
Steve Forte
Executive VP & CFO5.1yrsUS$1.93m0.034%
$ 40.5k
Maria Koehler
Executive VP & Chief Medical Officer5.5yrsUS$2.09m0.47%
$ 561.4k
Daniel Durocher
Co-Founderno datageen gegevensgeen gegevens
Frank Sicheri
Co-Founderno datageen gegevensgeen gegevens
Agnel Sfeir
Co-Founderno datageen gegevensgeen gegevens
Michael Zinda
Executive VP & Chief Scientific Officer5.5yrsUS$1.83m0.098%
$ 116.7k
Daniel Belanger
Executive Vice President of Human Resource1.5yrsgeen gegevens0.0037%
$ 4.4k
Cameron Black
Executive Vice President of Discovery8.4yrsgeen gegevens0.055%
$ 65.8k
Philip Herman
Executive VP2.8yrsgeen gegevens0.0092%
$ 11.0k

5.5yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van RPTX is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.5 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Lloyd Segal
President8.2yrsUS$4.99m0.28%
$ 331.2k
Ann Rhoads
Independent Director4.4yrsUS$274.74k0.0094%
$ 11.2k
David Bonita
Independent Director5.2yrsUS$265.41k0%
$ 0
Susan Molineaux
Independent Director1.4yrsUS$664.86k0%
$ 0
Steven Stein
Independent Directorless than a yeargeen gegevensgeen gegevens
Samarth Kulkarni
Independent Director5yrsUS$265.31k0%
$ 0
Thomas Civik
Independent Chairman3.2yrsUS$291.49k0.018%
$ 21.1k
Carol Schafer
Independent Director5.7yrsUS$272.99k0.019%
$ 22.5k

4.7yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RPTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.7 jaar).